Please use this identifier to cite or link to this item: https://doi.org/10.1186/1471-2334-14-142
DC FieldValue
dc.titleLong-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
dc.contributor.authorGillard, P
dc.contributor.authorChu, D.W.S
dc.contributor.authorHwang, S.-J
dc.contributor.authorYang, P.-C
dc.contributor.authorThongcharoen, P
dc.contributor.authorLim, F.S
dc.contributor.authorDramé, M
dc.contributor.authorWalravens, K
dc.contributor.authorRoman, F
dc.date.accessioned2020-10-27T11:08:33Z
dc.date.available2020-10-27T11:08:33Z
dc.date.issued2014
dc.identifier.citationGillard, P, Chu, D.W.S, Hwang, S.-J, Yang, P.-C, Thongcharoen, P, Lim, F.S, Dramé, M, Walravens, K, Roman, F (2014). Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infectious Diseases 14 (1) : 142. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2334-14-142
dc.identifier.issn14712334
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/181506
dc.description.abstractBackground: The pandemic potential of avian influenza A/H5N1 should not be overlooked, and the continued development of vaccines against these highly pathogenic viruses is a public health priority.Methods: This open-label extension booster study followed a Phase III study of 1206 adults who had received two 3.75 μg doses of primary AS03A-adjuvanted or non-adjuvanted H5N1 split-virus vaccine (A/Vietnam/1194/2004; clade 1) (NCT00449670). The aim of the extension study was to evaluate different timings for heterologous AS03A-adjuvanted booster vaccination (A/Indonesia/5/2005; clade 2.1) given at Month 6, 12, or 36 post-primary vaccination. Immunogenicity was assessed 21 days after each booster vaccination and the persistence of immune responses against the primary vaccine strain (A/Vietnam) and the booster strain (A/Indonesia) was evaluated up to Month 48 post-primary vaccination. Reactogenicity and safety were also assessed.Results: After booster vaccination given at Month 6, HI antibody responses to primary vaccine, and booster vaccine strains were markedly higher with one dose of AS03A-H5N1 booster vaccine in the AS03A-adjuvanted primary vaccine group compared with two doses of booster vaccine in the non-adjuvanted primary vaccine group. HI antibody responses were robust against the primary and booster vaccine strains 21 days after boosting at Month 12 or 36. At Month 48, in subjects boosted at Month 6, 12, or 36, HI antibody titers of ≥1:40 against the booster strain persisted in 39.2%, 61.2%, and 95.6% of subjects, respectively. Neutralizing antibody responses and cell-mediated immune responses also showed that AS03A-H5N1 heterologous booster vaccination elicited robust immune responses within 21 days of boosting at Month 6, 12, or 36 post-primary vaccination. The booster vaccine was well tolerated, and no safety concerns were raised.Conclusions: In Asian adults primed with two doses of AS03A-adjuvanted H5N1 pandemic influenza vaccine, strong cross-clade anamnestic antibody responses were observed after one dose of AS03A-H5N1 heterologous booster vaccine given at Month 6, 12, or 36 after priming, suggesting that AS03A-adjuvanted H5N1 vaccines may provide highly flexible prime-boost schedules. Although immunogenicity decreased with time, vaccinated populations could potentially be protected for up to three years after vaccination, which is likely to far exceed the peak of the a pandemic. © 2014 Gillard et al.; licensee BioMed Central Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectCD4 antibody
dc.subjectCD40 ligand
dc.subjectgamma interferon
dc.subjectimmunological adjuvant
dc.subjectinfluenza vaccine
dc.subjectinterleukin 2
dc.subjecttumor necrosis factor alpha
dc.subjectimmunological adjuvant
dc.subjectinfluenza vaccine
dc.subjectneutralizing antibody
dc.subjectacute kidney failure
dc.subjectadult
dc.subjectantibody response
dc.subjectantibody titer
dc.subjectappendicitis
dc.subjectarticle
dc.subjectAsian
dc.subjectavian influenza
dc.subjectbenign tumor
dc.subjectbrain disease
dc.subjectCD8+ T lymphocyte
dc.subjectcellular immunity
dc.subjectclavicle fracture
dc.subjectcolon polyp
dc.subjectcontrolled study
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectface fracture
dc.subjectfatigue
dc.subjectfemale
dc.subjectflu like syndrome
dc.subjectHelicobacter infection
dc.subjecthemagglutination inhibition test
dc.subjectHong Kong
dc.subjecthuman
dc.subjecthumoral immunity
dc.subjectileus
dc.subjectimmune response
dc.subjectimmunogenicity
dc.subjectimmunoreactivity
dc.subjectinfluenza A (H5N1)
dc.subjectInfluenza virus A H5N1
dc.subjectinjection site pain
dc.subjectjoint dislocation
dc.subjectligament rupture
dc.subjectlung embolism
dc.subjectlymphadenopathy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmyalgia
dc.subjectovary tumor
dc.subjectpandemic influenza
dc.subjectphase 3 clinical trial
dc.subjectpyelonephritis
dc.subjectrhinopharyngitis
dc.subjectSingapore
dc.subjectTaiwan
dc.subjectThailand
dc.subjecttonsillitis
dc.subjecttooth disease
dc.subjectvaccination
dc.subjectvirus neutralization
dc.subjectvirus strain
dc.subjectArticle
dc.subjectcross reaction
dc.subjectevaluation study
dc.subjectinfluenza A (H5N1)
dc.subjectinfluenza vaccination
dc.subjectinjection site reaction
dc.subjectopen study
dc.subjectrandomized controlled trial
dc.subjectAdult
dc.subjectalpha-Tocopherol
dc.subjectAnimals
dc.subjectAntibodies, Neutralizing
dc.subjectAntibodies, Viral
dc.subjectAsian Continental Ancestry Group
dc.subjectCross Reactions
dc.subjectDrug Combinations
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunization Schedule
dc.subjectImmunization, Secondary
dc.subjectInfluenza A Virus, H5N1 Subtype
dc.subjectInfluenza Vaccines
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPolysorbates
dc.subjectSqualene
dc.subjectYoung Adult
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1186/1471-2334-14-142
dc.description.sourcetitleBMC Infectious Diseases
dc.description.volume14
dc.description.issue1
dc.description.page142
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_1471-2334-14-142.pdf311.34 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons